KUDOS PHARMACEUTICALS LIMITED
Get an alert when KUDOS PHARMACEUTICALS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-12-26 (in 7mo)
Last made up 2025-12-12
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£2B
+61.9% vs 2023
Employees
0
Average over period
Profit before tax
£705M
-17.6% vs 2023
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £670,000,000 | £980,000,000 | |
| Operating profit | £853,000,000 | £633,000,000 | |
| Profit before tax | £856,000,000 | £705,000,000 | |
| Net profit | £813,000,000 | £634,000,000 | |
| Cash | — | — | |
| Total assets less current liabilities | £1,017,000,000 | £1,673,000,000 | |
| Net assets | £1,024,000,000 | £1,658,000,000 | |
| Equity | £1,024,000,000 | £1,658,000,000 | |
| Average employees | 0 | 0 | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 127.3% | 64.6% | |
| Net margin | 121.3% | 64.7% | |
| Return on capital employed | 83.9% | 37.8% | |
| Gearing (liabilities / total assets) | 16.3% | 12.1% | |
| Current ratio | 7.52x | 10.04x | |
| Interest cover | 65.62x | 633.00x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors, in concluding that the going concern basis is appropriate, have received from AstraZeneca PLC a letter of support confirming that AstraZeneca PLC will continue to provide the financial resources required to fund the Company's operations for the foreseeable future and at least 12 months from the date of signing the Financial Statements. After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Based on their assessment of the Company's financial position, they continue to adopt the going concern basis in preparing the Financial Statements.”
Group structure
- KUDOS PHARMACEUTICALS LIMITED · parent
- KUDOS Horsham Limited 100%
Significant events
- “In February 2025, the Company declared and paid dividends of £1,000m (£159 per share) to AstraZeneca UK Limited.”
- “The Company received a Paragraph IV notice relating to Lynparza patent from Natco Pharma Limited (Natco) in December 2022, Sandoz Inc. (Sandoz) in December 2023, Cipla USA, Inc. and Cipla Limited (collectively, Cipla) in May 2024, and Zydus Pharmaceuticals (USA) Inc. (Zydus) in November 2024.”
- “In June 2024, the Company was served with a lawsuit filed by the University of Sheffield (Sheffield) alleging that the Company made misrepresentations to induce Sheffield to amend a patent license relating to Lynparza. The Company filed its defence in August 2024.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
8 active · 30 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| JOHNSTONE, Camilla Jane | Secretary | 2019-09-16 | — | — |
| BOWDEN, Matthew Shaun | Director | 2019-02-27 | Dec 1977 | British |
| COLLINS, Iain Alistair | Director | 2017-05-31 | Dec 1970 | British |
| GALBRAITH, Susan | Director | 2024-06-28 | Oct 1965 | British |
| SAMBROOK, Sally | Director | 2024-06-28 | Feb 1973 | British |
| SARIN, Aradhana | Director | 2024-06-28 | Apr 1974 | American |
| STEPHENS, Christine | Director | 2024-06-28 | Apr 1971 | British |
| TATTERSALL, Hannah Victoria | Director | 2025-05-01 | Jul 1987 | British |
Show 30 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BURR, Kenneth Edward | Secretary | 1999-03-09 | 2002-03-04 |
| CONACHER, Matthew Ian | Secretary | 2017-03-16 | 2019-09-16 |
| DALLY, David James Michael | Secretary | 2002-03-04 | 2006-01-31 |
| HOSKINS, Justin Wilbert | Secretary | 2006-11-20 | 2011-12-16 |
| JACKSON-TURNER, Katie Louise | Secretary | 2015-07-15 | 2017-03-16 |
| KEMP, Adrian Charles Noel | Secretary | 2006-01-31 | 2006-11-20 |
| O'GRADY, Claire-Marie | Secretary | 2011-12-16 | 2015-07-31 |
| WALLACE, Roderick Iain | Secretary | 1997-12-12 | 1999-03-09 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Secretary | 1997-12-12 | 1997-12-12 |
| AUTY, Richard Maitland, Dr | Director | 2003-03-19 | 2006-01-31 |
| BENJAMIN, Jerry Christopher | Director | 1999-03-02 | 2000-06-30 |
| BLUNDY, Keith Stuart, Dr | Director | 1999-12-17 | 2002-08-28 |
| BRIMICOMBE, Ian Martin David | Director | 2006-01-31 | 2017-05-31 |
| CARTER, Michael Greenwood, Doctor | Director | 1999-03-02 | 2006-01-31 |
| FODEN, Susan Elizabeth, Dr | Director | 1997-12-12 | 1999-11-10 |
| JACKSON, Stephen Philip | Director | 1997-12-12 | 2006-01-31 |
| JACKSON-TURNER, Katie Louise | Director | 2017-03-16 | 2019-02-27 |
| JENNINGS, Richard Charles, Dr | Director | 1997-12-12 | 1999-03-02 |
| KEMP, Adrian Charles Noel | Director | 2009-01-01 | 2025-05-01 |
| KUIJTEN, Rene Robert | Director | 2002-08-28 | 2006-01-31 |
| LAMBERT, Susan | Director | 2002-08-28 | 2003-11-05 |
| LEE, Patrick Pak Tin | Director | 2000-07-01 | 2006-01-31 |
| LONG, Ronald Eric | Director | 2001-01-01 | 2006-01-31 |
| MANSFORD, Keith, Doctor | Director | 1997-12-12 | 2001-01-01 |
| MUSKER, Graeme Harold Rankine | Director | 2006-01-31 | 2008-12-31 |
| PETTY, Cathrin | Director | 1999-03-02 | 2000-05-09 |
| THURSTON, Julian Paul | Director | 1997-12-12 | 1998-10-30 |
| WARD, John Barrie, Dr | Director | 1999-03-02 | 2006-01-31 |
| WHITAKER, Raymond, Dr | Director | 2002-08-28 | 2006-01-31 |
| ZEHAVI, Zeev | Director | 2003-11-05 | 2006-01-31 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Astrazeneca Uk Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 223 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-11-27 RESOLUTIONS Resolution
- 2024-11-27 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-08-07 | AA | accounts | Accounts with accounts type full | |
| 2025-05-02 | AP01 | officers | Appoint person director company with name date | |
| 2025-05-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-12-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-11-27 | RESOLUTIONS | resolution | Resolution | |
| 2024-11-27 | MA | incorporation | Memorandum articles | |
| 2024-08-28 | CH01 | officers | Change person director company with change date | |
| 2024-08-02 | AA | accounts | Accounts with accounts type full | |
| 2024-07-10 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-10 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-10 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-10 | AP01 | officers | Appoint person director company with name date | |
| 2023-12-18 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-09-14 | AA | accounts | Accounts with accounts type full | |
| 2022-12-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-08-16 | CH01 | officers | Change person director company with change date | |
| 2022-08-05 | AA | accounts | Accounts with accounts type full | |
| 2021-12-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-12-06 | CH01 | officers | Change person director company with change date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+46.3%
£670,000,000 £980,000,000
-
Cash
—
Not reported
-
Net assets
+61.9%
£1,024,000,000 £1,658,000,000
-
Employees
—
Not reported
-
Operating profit
-25.8%
£853,000,000 £633,000,000
-
Profit before tax
-17.6%
£856,000,000 £705,000,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers